Lipocine Inc. — Director's Dealing 2017

Feb 1, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lipocine Inc. (LPCN)
CIK: 0001535955
Period of Report: 2017-02-01

Reporting Person: Bass Gregory Brooks (EVP and Chief Commercial Offic)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Unit	$0	2027-01-25	Common Stock (37500)		Direct
Stock Option (Right to Buy)	$3.61	2026-12-06	Common Stock (35000)		Direct
Stock Option (Right to Buy)	$9.21	2026-01-31	Common Stock (55000)		Direct

Footnotes

F1: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.

F2: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit

F3: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years.

F4: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of February 1, 2017, while the remaining 2/3 of the shares subject to the award vest monthly on a prorata basis over the following two years.